» Articles » PMID: 23936385

The Efficacy of an Immunoisolating Membrane System for Islet Xenotransplantation in Minipigs

Abstract

Developing a device that protects xenogeneic islets to allow treatment and potentially cure of diabetes in large mammals has been a major challenge in the past decade. Using xenogeneic islets for transplantation is required in light of donor shortage and the large number of diabetic patients that qualify for islet transplantation. Until now, however, host immunoreactivity against the xenogeneic graft has been a major drawback for the use of porcine islets. Our study demonstrates the applicability of a novel immunoprotective membrane that allows successful xenotransplantation of rat islets in diabetic minipigs without immunosuppressive therapy. Rat pancreatic islets were encapsulated in highly purified alginate and integrated into a plastic macrochamber covered by a poly-membrane for subcutaneous transplantation. Diabetic Sinclair pigs were transplanted and followed for up to 90 days. We demonstrated a persistent graft function and restoration of normoglycemia without the need for immunosuppressive therapy. This concept could potentially offer an attractive strategy for a more widespread islet replacement therapy that would restore endogenous insulin secretion in diabetic patients without the need for immunosuppressive drugs and may even open up an avenue for safe utilization of xenogeneic islet donors.

Citing Articles

Xenogenic Engraftment of Human-Induced Pluripotent Stem Cell-Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-Pig Model.

Yamasaki M, Maki T, Mochida T, Hamada T, Watanabe-Matsumoto S, Konagaya S Cell Transplant. 2024; 33:9636897241288932.

PMID: 39401129 PMC: 11489945. DOI: 10.1177/09636897241288932.


High-Efficiency, Prevascularization-Free Macroencapsulation System for Subcutaneous Transplantation of Pancreatic Islets for Enhanced Diabetes Treatment.

Jeon S, Heo J, Myung N, Shin J, Kim M, Kang H Adv Mater. 2024; 36(50):e2408329.

PMID: 39308296 PMC: 11636157. DOI: 10.1002/adma.202408329.


Impact of oxygen and glucose availability on the viability and connectivity of islet cells: A computational study of reconstructed avascular human islets.

Felix-Martinez G, Osorio-Londono D, Godinez-Fernandez J PLoS Comput Biol. 2024; 20(8):e1012357.

PMID: 39137218 PMC: 11343470. DOI: 10.1371/journal.pcbi.1012357.


Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression.

Wang L, Marfil-Garza B, Ernst A, Pawlick R, Pepper A, Okada K Nat Biomed Eng. 2023; 8(10):1266-1284.

PMID: 38052996 DOI: 10.1038/s41551-023-01145-8.


Combinatorial islet protective therapeutic approaches in β-cell transplantation: Rationally designed solutions using a target product profile.

Lu K, Brauns T, Sluder A, Poznansky M, Dogan F FASEB Bioadv. 2023; 5(7):287-304.

PMID: 37415930 PMC: 10320848. DOI: 10.1096/fba.2023-00029.


References
1.
Lehmann R, Zuellig R, Kugelmeier P, Baenninger P, Moritz W, Perren A . Superiority of small islets in human islet transplantation. Diabetes. 2007; 56(3):594-603. DOI: 10.2337/db06-0779. View

2.
Jansson L . The regulation of pancreatic islet blood flow. Diabetes Metab Rev. 1994; 10(4):407-16. DOI: 10.1002/dmr.5610100405. View

3.
Shapiro A, Ricordi C, Hering B, Auchincloss H, Lindblad R, Robertson R . International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006; 355(13):1318-30. DOI: 10.1056/NEJMoa061267. View

4.
Barton F, Rickels M, Alejandro R, Hering B, Wease S, Naziruddin B . Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012; 35(7):1436-45. PMC: 3379615. DOI: 10.2337/dc12-0063. View

5.
Specke V, Plesker R, Wood J, Coulibaly C, Suling K, Patience C . No in vivo infection of triple immunosuppressed non-human primates after inoculation with high titers of porcine endogenous retroviruses. Xenotransplantation. 2009; 16(1):34-44. DOI: 10.1111/j.1399-3089.2009.00508.x. View